Cebranopadol

Drug Profile

Cebranopadol

Alternative Names: GRT-6005

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Grunenthal
  • Developer Allergan; Grunenthal
  • Class Cyclohexylamines; Indoles; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nociceptin receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Back pain; Diabetic neuropathies; Musculoskeletal pain
  • No development reported Postoperative pain

Most Recent Events

  • 30 Sep 2016 Efficacy and adverse events data from a phase III trial in Cancer pain released by Grunenthal
  • 01 May 2016 Grünenthal completes the phase III CORAL XT extension trial for Cancer pain in Austria, Belgium, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia, Sweden, the UK, Spain, Bulgaria, the Netherlands and Croatia (NCT02031432, EudraCT2013-001877-26)
  • 25 Nov 2015 Grunenthal terminates a phase III trial in Cancer pain in UK, Austria, Denmark, Germany, Hungary, Belgium, Slovakia, Croatia, Poland, Romania, Bulgaria, Chile, Spain, Sweden, the Netherlands and Serbia (NCT01964378)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top